Cantor Fitzgerald Estimates MLTX FY2025 Earnings

MoonLake Immunotherapeutics (NASDAQ:MLTX) – Equities researchers at Cantor Fitzgerald issued their FY2025 earnings estimates for MoonLake Immunotherapeutics in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst P. Agrawal forecasts that the company will post earnings of ($1.91) per share for the year. The consensus estimate for MoonLake Immunotherapeutics’ current full-year earnings is ($1.75) per share.

MLTX has been the subject of several other research reports. HC Wainwright reissued a “buy” rating and issued a $100.00 price target on shares of MoonLake Immunotherapeutics in a research note on Friday, January 10th. Wedbush reaffirmed an “outperform” rating and set a $73.00 target price (down previously from $92.00) on shares of MoonLake Immunotherapeutics in a research report on Tuesday, November 5th. Finally, The Goldman Sachs Group upgraded MoonLake Immunotherapeutics from a “neutral” rating to a “buy” rating and upped their price target for the stock from $62.00 to $82.00 in a report on Friday, January 17th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $84.29.

MoonLake Immunotherapeutics Stock Performance

NASDAQ MLTX opened at $47.11 on Thursday. MoonLake Immunotherapeutics has a 1 year low of $37.55 and a 1 year high of $64.98. The stock’s 50-day moving average price is $51.23 and its two-hundred day moving average price is $49.08.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.12). During the same period in the previous year, the company posted ($0.18) EPS.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of MoonLake Immunotherapeutics by 96.4% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 35,814 shares of the company’s stock worth $1,806,000 after acquiring an additional 17,580 shares during the period. Erste Asset Management GmbH acquired a new stake in MoonLake Immunotherapeutics during the 3rd quarter worth approximately $741,000. State Street Corp lifted its holdings in MoonLake Immunotherapeutics by 96.2% during the 3rd quarter. State Street Corp now owns 87,637 shares of the company’s stock worth $4,419,000 after purchasing an additional 42,980 shares during the last quarter. Barclays PLC raised its holdings in MoonLake Immunotherapeutics by 1,269.2% in the 3rd quarter. Barclays PLC now owns 5,641 shares of the company’s stock valued at $283,000 after acquiring an additional 5,229 shares in the last quarter. Finally, Harbor Capital Advisors Inc. raised its holdings in MoonLake Immunotherapeutics by 100.2% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 77,468 shares of the company’s stock valued at $3,906,000 after acquiring an additional 38,779 shares in the last quarter. 93.85% of the stock is currently owned by institutional investors.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.